**Safety and immune-supportive potential of food supplement 5-amionolevulinic acid phosphate in coronavirus disease 2019: An open-lable, non-randomized pilot study**

**Abdulla** **Darwish1, Abdulrahman Almadani1, Jameela Alsalman2, Stephen Atkin3, Mariam Murad3, Motowo Nakajima4, Riyadh Rehani5, Andrea Ebeling5, Marcus Stocker5, Walter Stummer6, Norbert Berenzen5\***

1Department of Pathology & Surgery, Bahrain Defense Force hospital, West Riffa, Kingdom of Bahrain

2Infection Disease Unit, Department of Internal Medicine, Salmaniya Medical Complex, Manama, Kingdom of Bahrain

3Department School of Medicine,Royal College of Surgeons in Ireland- Medical University of Bahrain, Manama, Kingdom of Bahrain

4Research and Development Department, SBI Pharmaceutical Co, Ltd., Tokyo, Japan

5Clinical Project Management Department, Photonamic GmbH and Co. KG, Pinneberg, Germany

6Department of Neurosurgery,University Hospital Muenster, Muenster, Germany

**\*Corresponding author****:**

Norbert Berenzen, Ph.D.

Photonamic GmbH and Co. KG

Eggerstedter Weg 12, Pinneberg 25421, Germany

Phone: +49 4101 785 34 43

Fax: +49 4101 784 94 02

E-mail: n.berenzen@photonamic.de

https://orcid.org/0009-0003-6885-2533

Email Addresses of all Authors

1. Abdulla Darwish, abdulla.darwish@bdfmedical.org

2. Abdulrahman Almadani, dr\_almadani@hotmail.com

3. Mariam Murad, mmurad@rcsi.com

4. Jameela Alsalman, jsalman@health.gov.bh

5. Motowo Nakajima, motnakaj@sbigroup.co.jp

6. Riyadh Rehani, r.rehani@photonamic.de

7. Andrea Ebeling, a.ebeling@photonamic.de

8. Marcus Stocker, m.stocker@photonamic.de

9. Walter Stummer, walter.stummer@ukmuenster.de

10. Stephen L Atkin, satkin@rcsi.com

11. Norbert Berenzen, [n.berenzen@photonamic.de\*](mailto:n.berenzen@photonamic.de*)

**Ethical Approval**

This open-label, interventional, and exploratory pilot study was approved by the ethical committees of the Bahrain Defense Hospital, National Health Regulatory Authority and COVID-19 Committee of Bahrain. This study was conducted following good clinical practice and in accordance with the guidelines of the Declaration of Helsinki. All patients provided written informed consent. Data integrity and quality were regularly checked by a clinical monitor during on-site monitoring visits.

**Trial Registration**: The study was registered on ClinicalTrials.gov (https://clinicaltrials.gov/) on September 06, 2020 (registration no. NCT04542850).

**Competing Interests**

Andrea Ebeling, Riyadh Rehani, Marcus Stocker, and Norbert Berenzen are employees of photonamic GmbH and Co. KG. However, none of these authors have further financial arrangements (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, research support, or major honorary). Motowo Nakajima is an employee of SBI Holdings and a shareholder of SBI ALA Pharma Japan; the study product was provided by SBI Pharmaceuticals, which is part of SBI Holdings. Walter Stummer is a consultant for SBI ALA Pharma and receives fees for consultancy. The remaining authors declare no conflicts of interest.

**Author Contributions**

Motowo Nakajima, Andrea Ebeling, Riyadh Rehani, Walter Stummer, Marcus Stocker, Norbert Berenzen, and Stephen Atkin designed and supervised the study. Abdulla Darwish and Abdulrahman Almadani were investigators at BDF Hospital, Jameela Alsalman was an investigator at Salmaniya Medical Complex. Mariam Murad was responsible for project administration. Riyadh Rehani, Stephen Atkin, and Norbert Berenzen wrote the manuscript. Norbert Berenzen was primarily responsible for final content and editing. All the authors have read and approved the final version of this manuscript.

**ACKNOWLEDGEMENTS AND FUNDING**

This study was funded by photonamic GmbH and Co. KG, Pinneberg, Germany.

We thank Ph. Yaser Sakheer Alameeri, Head of Medical Supplies and Directorate of Maintenance & Material Supplies at the Bahrain Defense Force Royal Medical Services, Riffa, Kingdom of Bahrain, for his support with the import, storage, and supply of the study product to sites. We also thank Aslam Mohamed Sadiq for clinical monitoring and ensuring patient safety and data integrity. Moreover, we thank Vedic Lifesciences for the statistical analysis and evaluation of the study results as well as Edi Berentzen for designing and artistic realization of the figures included. The study products were provided by SBI Pharmaceuticals Co. Ltd. (Tokyo, Japan). We would like to thank Editage (www.editage.com) for English language editing.